This report summarizes a prospective trial evaluating the sleep oximeter accuracy of the RPMO2 OSA Device in obstructive sleep apnea.
Publication date context is February 20, 2026. The study is listed on ClinicalTrials.gov under NCT07397780 with Obstructive Sleep Apnea as the condition and RPMO2 OSA Device as the intervention. Sponsor ProSomnus Sleep Technologies is described as overseeing the trial, which is currently active and not recruiting. The entry frames the work as an accuracy evaluation of a device used during sleep. The record also notes that basic information on endpoints and design details is not disclosed in the provided extract. For reference, the full listing can be found on ClinicalTrials.gov at the provided link.
As a regulatory minded update the entry frames the trial as an accuracy evaluation and highlights that the device is intended to measure oxygen saturation during sleep and may inform sleep apnea management decisions. This information is of interest to clinicians, researchers, and regulatory affairs teams assessing device performance claims.
In this article
- What is the trial?
- What regulatory context surrounds this trial?
- What is the RPMO2 OSA Device?
- What is known about timeline and updates?
- Sponsor perspective and regulatory implications
What is the RPMO2 OSA Device trial evaluating?
The trial addresses the accuracy of the RPMO2 OSA Device during sleep in people with obstructive sleep apnea. The entry notes the condition, the intervention, and sponsor involvement. The design is described as an active, not recruiting trial on ClinicalTrials.gov. The population details are not disclosed in the provided text, and the record does not reveal endpoints or statistical plans. The primary focus is the device accuracy during sleep, which regulatory minded readers interpret as a performance assessment rather than a standard therapeutic efficacy study. The sponsor is ProSomnus Sleep Technologies and the device under study is the RPMO2 OSA Device. The listing includes a direct reference to the ClinicalTrials.gov page for traceability.
Population and design
The source identifies obstructive sleep apnea as the condition and the RPMO2 OSA Device as the intervention. Sponsor is listed as ProSomnus Sleep Technologies. Specifics on sample size, randomization, trial phase, or endpoints are not provided in the text. The status active not recruiting indicates ongoing data collection within a defined regulatory framework.
Outcome measures
Outcome measures are not detailed in the extract. Readers are advised to monitor official listings for defined endpoints, performance thresholds, and safety considerations as data become available.
What regulatory context surrounds this trial?
The trial is listed on ClinicalTrials.gov and aims to provide evidence on device performance within a regulatory framework for medical devices. The source does not indicate clearance status or regulatory submissions. The MDR style interpretation regards the trial as an accuracy evaluation that informs intended use and performance claims while maintaining safety considerations. Readers should monitor updates for endpoints safety observations and data disclosure.
What is the RPMO2 OSA Device and its role in the trial?
The RPMO2 OSA Device is listed as the intervention in this trial. The source provides no further device feature information. Sponsor ProSomnus Sleep Technologies is a company focused on sleep wellness devices for obstructive sleep apnea. The trial framing presents the device as an accuracy evaluation tool rather than a traditional efficacy trial.
Timeline and updates
As of February 20 2026 the trial status remains active and not recruiting. No results are posted within the provided source text. Stakeholders should anticipate future updates on the ClinicalTrials.gov listing or through sponsor communications. Early stage studies of this type often deliver data in subsequent updates, reflecting performance characteristics and safety observations as they are collected.
Sponsor perspective and regulatory implications
ProSomnus Sleep Technologies sponsors the RPMO2 OSA Device trial. The sponsor involvement signals an intent to build evidence around device performance for sleep apnea related use. Regulators will expect rigorous reporting of methods endpoints and any safety observations. Until data are released the regulatory status remains in development and the record serves as a focal point for health care professionals evaluating potential device claims.
FAQ
- 1. What is being tested in this trial?
The focus is on the accuracy of the RPMO2 OSA Device as an oximeter during sleep in obstructive sleep apnea. - 2. Who is conducting the trial?
The sponsor is ProSomnus Sleep Technologies. The device under study is RPMO2 OSA Device. - 3. What is the trial status?
According to the source the trial is active and not recruiting. - 4. Where can I find the official listing?
The ClinicalTrials.gov listing is NCT07397780 with the link provided in the source text.
Conclusion and what this means for clinicians and regulators
This trial represents a structured effort to validate sleep oximeter accuracy for the RPMO2 OSA Device in obstructive sleep apnea. The current status is active but not recruiting which means formal results are not yet available. Stakeholders should track the ClinicalTrials.gov listing and sponsor communications for data releases endpoints and safety observations.
This content is for professional use and does not constitute legal advice. It reflects information in the source text and any cited sources. For legal guidance consult appropriate regulatory counsel.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07397780?term=medical+device